Diagnostic utility of an anti-CCP point-of-care immunotest in Chinese patients with rheumatoid arthritis

Clinica Chimica Acta

Volumn 412, Issue 9-10, 2011, Pages 778-781

  Liao, Jun ^a   Ip, Wai sze ^b   Cheung, Kwan yee ^c   Wan, Wai man ^b   Cautherley, George W H ^c   Cai, Xiaoyan ^a   Lin, Xiaojun ^a   Renneberg, Reinhard ^b   Chan, Cangel Pui yee ^d  

^a GUANGZHOU FIRST PEOPLE'S HOSPITAL   (China)

^b HONG KONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Hong Kong)

^c R and C Biogenius Limited   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Anti cyclic citrullinated peptide (anti CCP); Point of care (POC); Rheumatic diseases; Rheumatoid arthritis (RA); Rheumatoid factor (RF)

Indexed keywords

CYCLIC CITRULLINATED PEPTIDE ANTIBODY; RHEUMATOID FACTOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHINESE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; RELIABILITY; RHEUMATOID ARTHRITIS; SENSITIVITY AND SPECIFICITY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES; ARTHRITIS, RHEUMATOID; ASIAN CONTINENTAL ANCESTRY GROUP; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; POINT-OF-CARE SYSTEMS; SEROLOGIC TESTS; TIME FACTORS; YOUNG ADULT;

EID: 79951726465     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2011.01.013     Document Type: Article

References (30)

1. Zeng Q.Y., Chen R., Darmawan J., et al. Rheumatic diseases in China. Arthritis Res Ther 2008, 10(1):R17.
2. Egerer K., Feist E., Burmester G.R. The serological diagnosis of rheumatoid arthritis: antibodies to citrullinated antigens. Dtsch Arztebl Int 2009, 106(10):159-163.
3. Schellekens G.A., Visser H., de Jong B.A., et al. The diagnostic properties of rheumatoid arthritis antibodies recognizing a cyclic citrullinated peptide. Arthritis Rheum 2000, 43:155-163.
4. Suzuki K., Sawada T., Murakami A., et al. High diagnostic performance of ELISA detection of antibodies to citrullinated antigens in rheumatoid arthritis. Scand J Rheumatol 2003, 32:197-204.
5. Zeng X., Ai M., Tian X., et al. Diagnostic value of anti-cyclic citrullinated peptide antibody in patients with rheumatoid arthritis. J Rheumatol 2003, 30:1451-1455.
6. Kastbom A., Strandberg G., Lindroos A. Anti-CCP antibody test predicts the disease course during 3years in early rheumatoid arthritis (the Swedish TIRA project). Ann Rheum Dis 2004, 63:1085-1089.
7. Kroot E.J., de Jong B.A., van Leeuwen M.A., et al. The prognostic value of anti-cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000, 43:1831-1835.
8. Bongi S.M., Manetti R., Melchiorre D., et al. Anti-cyclic citrullinated peptide antibodies are highly associated with severe bone lesions in rheumatoid arthritis: anti-CCP and bone damage in RA. Autoimmunity 2004, 37:495-501.
9. Arnett F.C., Edworthy S.M., Bloch D.A., McShane D.J., Fries J.F., Cooper N.S. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988, 31:315-324.
10. Moll J.M.H., Wright V. Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55-78.
11. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
12. Chinese Rheumatology Association Guidelines for diagnosis of gout (Draft). Chin J Rheumatol 2004, 8(3):178-181.
13. Alarcon-Segovia D., Villareal M. Classification and diagnostic criteria for MCTD. Mixed connective tissue disease and antinuclear antibodies 1987, 30-40. Elsevier, Amsterdam. R. Kasukawa, G.C. Sharp (Eds.).
14. Visser H., le Cessie S., Vos K., Breedveld F.C., Hazes J.M. How to diagnose rheumatoid arthritis early: a prediction model for persistent (erosive) arthritis. Arthritis Rheum 2002, 46:357-365.
15. Saraux A., Berthelot J.M., Chales G., et al. Ability of the American College of Rheumatology 1987 criteria to predict rheumatoid arthritis in patients with early arthritis and classification of these patients two years later. Arthritis Rheum 2001, 44:2485-2491.
16. Zendman A.J.W., van Venrooij W.J., Pruijn G.J.M. Use and significance of anti-CCP autoantibodies in rheumatoid arthritis. Rheumatology 2006, 45:20-25.
17. Aletaha D., Neogi T., Silman A.J., et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
18. Pruijn G.J., Wiik A., van Venrooij W.J. The use of citrullinated peptides and proteins for the diagnosis of rheumatoid arthritis. Arthritis Res Ther 2010, 12(1):203.
19. Bas S., Perneger T.V., Kunzle E., Vischer T.L. Comparative study of different enzyme immunoassays for measurement of IgM and IgA rheumatoid factors. Ann Rheum Dis 2002, 61:505-510.
20. Saraux A., Berthelot J.M., Devauchelle V., et al. Value of antibodies to citrulline-containing peptides for diagnosing early rheumatoid arthritis. J Rheumatol 2003, 30:2535-2539.
21. Jansen L.M., van Schaardenburg D., van der Horst-Bruinsma I., van der Stadt R.J., de Koning M.H., Dijkmans B.A. The predictive value of anti-cyclic citrullinated peptide antibodies in early arthritis. J Rheumatol 2003, 30:1691-1695.
22. Kwok J.S.Y., Hui K.H., Lee T.L., et al. Anti-cyclic citrullinated peptide: diagnostic and prognostic values in juvenile idiopathic arthritis and rheumatoid arthritis in a Chinese population. Scand J Rheumatol 2005, 34:359-366.
23. Kastbom A., Strandberg G., Lindroos A., Skogh T. Anti-CCP antibody test predicts the disease course during 3years in early rheumatoid arthritis. Ann Rheum Dis 2004, 63:1085-1089.
24. Inanc N., Dalkilic E., Kamali S., et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007, 26:17-23.
25. Korendowych E., Owen P., Ravindran J., Carmichael C., McHugh N. The clinical and genetic associations of anti-cyclic citrullinated peptide antibodies in psoriatic arthritis. Rheumatology 2005, 44:1056-1060.
26. Inanc N., Dalkilic E., Kamali S., et al. Anti-CCP antibodies in rheumatoid arthritis and psoriatic arthritis. Clin Rheumatol 2007, 26:17-23.
27. Abdel Fattah N.S., Hassan H.E., Galal Z.A., El Okda el S.E. Assessment of anti-cyclic citrullinated peptide in psoriatic arthritis. BMC Res Notes 2009, 2:44.
28. Vander Cruyssen B., Hoffman I.E.A., Zmierczak H., et al. Anti-citrullinated peptide antibodies may occur in patients with psoriatic arthritis. Ann Rheum Dis 2005, 64:1145-1149.
29. O'Dell J.R. Treating rheumatoid arthritis early: a window of opportunity?. Arthritis Rheum 2002, 46:283-285.
30. Snijders G.F., Broeder A.A., Bevers K., Jeurissen M.E., van Eerd J.E., van den Hoogen F.H. Measurement characteristics of a new rapid anti-CCP2 testcompared to the anti-CCP2 ELISA. Scand J Rheumatol 2008, 37:151-154.